Extended Data Fig. 8: Forest plot of efficacy outcomes by PD-L1 CPS with nivolumab plus ipilimumab versus chemotherapy.
From: Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
a, Overall survival. Data are presented as unstratified HRs and 95% CI. b, Objective response rate. aPD-L1 CPS expression indeterminate/not evaluable/not reported, n = 15; bRandomized patients who had target lesion measurements at baseline, per blinded independent central review assessment; cPD-L1 CPS expression indeterminate/not evaluable/not reported, n = 10; dPercentages may not reflect an exact difference due to rounding. Data are presented as unweighted ORR differences and 95% CI. Chemo, chemotherapy; CI, confidence interval; CPS, combined positive score; HR, hazard ratio; IPI, ipilimumab; NIVO, nivolumab; ORR, objective response rate; OS, overall survival; PD-L1, programmed death ligand 1.
